Divi’s Labs Q4 net up 13% to ₹751 cr., declares ₹30 dividend

Generic drugmaker Divi’s Laboratories reported consolidated net profit for March quarter increased more than 13% to ₹751 crore compared to ₹662 crore a year earlier.

The higher profit came on a consolidated total income of ₹2,986 crore (₹2,671 crore). Foreign exchange gain for the quarter was ₹90 crore (₹10 crore).

The active pharmaceutical ingredient, intermediates and nutraceutical ingredients maker has declared a final dividend of ₹30 per equity share (face value of ₹2 each) for 2025-26 and fixed July 24 as the record date, for the same.

For FY26, the company posted net profit of ₹2,568 crore (₹2,191 crore) on a total income of ₹11,067 crore (₹9,712 crore). The forex gain during the fiscal was ₹211 crore (₹48 crore).